Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C16H20Cl2N2O |
Molecular Weight | 327.249 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CO\N=C\[C@H]1[C@H]2CC[C@@H](C[C@@H]1C3=CC=C(Cl)C(Cl)=C3)N2C
InChI
InChIKey=NRLIFEGHTNUYFL-QJDHNRDASA-N
InChI=1S/C16H20Cl2N2O/c1-20-11-4-6-16(20)13(9-19-21-2)12(8-11)10-3-5-14(17)15(18)7-10/h3,5,7,9,11-13,16H,4,6,8H2,1-2H3/b19-9+/t11-,12+,13+,16+/m0/s1
Molecular Formula | C16H20Cl2N2O |
Molecular Weight | 327.249 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
NeuroSearch was developing brasofensine (or NS 2214), an oral dopamine reuptake inhibitor for the treatment of Parkinson's disease. Brasofensine successfully passed phase II clinical trial in patients with Parkinson's disease, The drug was safe and well tolerated. However, NeuroSearch discontinued the development of the drug because of the cis-anti isomerization of the 2α-methyloxime group of brasofensine in favor of NS 2230.
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11847938
a single oral dose of brasofensine 0.5, 1, 2, or 4 mg, which was coadministered with the patient's usual dose of levodopa/carbidopav
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:20:46 GMT 2023
by
admin
on
Sat Dec 16 17:20:46 GMT 2023
|
Record UNII |
1YP2S94RVH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C38149
Created by
admin on Sat Dec 16 17:20:47 GMT 2023 , Edited by admin on Sat Dec 16 17:20:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID00905102
Created by
admin on Sat Dec 16 17:20:47 GMT 2023 , Edited by admin on Sat Dec 16 17:20:47 GMT 2023
|
PRIMARY | |||
|
SUB05881MIG
Created by
admin on Sat Dec 16 17:20:47 GMT 2023 , Edited by admin on Sat Dec 16 17:20:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL2104184
Created by
admin on Sat Dec 16 17:20:47 GMT 2023 , Edited by admin on Sat Dec 16 17:20:47 GMT 2023
|
PRIMARY | |||
|
100000088658
Created by
admin on Sat Dec 16 17:20:47 GMT 2023 , Edited by admin on Sat Dec 16 17:20:47 GMT 2023
|
PRIMARY | |||
|
C415103
Created by
admin on Sat Dec 16 17:20:47 GMT 2023 , Edited by admin on Sat Dec 16 17:20:47 GMT 2023
|
PRIMARY | |||
|
171655-91-7
Created by
admin on Sat Dec 16 17:20:47 GMT 2023 , Edited by admin on Sat Dec 16 17:20:47 GMT 2023
|
PRIMARY | |||
|
9614919
Created by
admin on Sat Dec 16 17:20:47 GMT 2023 , Edited by admin on Sat Dec 16 17:20:47 GMT 2023
|
PRIMARY | |||
|
C76391
Created by
admin on Sat Dec 16 17:20:47 GMT 2023 , Edited by admin on Sat Dec 16 17:20:47 GMT 2023
|
PRIMARY | |||
|
7530
Created by
admin on Sat Dec 16 17:20:47 GMT 2023 , Edited by admin on Sat Dec 16 17:20:47 GMT 2023
|
PRIMARY | |||
|
BRASOFENSINE
Created by
admin on Sat Dec 16 17:20:47 GMT 2023 , Edited by admin on Sat Dec 16 17:20:47 GMT 2023
|
PRIMARY | |||
|
DB04857
Created by
admin on Sat Dec 16 17:20:47 GMT 2023 , Edited by admin on Sat Dec 16 17:20:47 GMT 2023
|
PRIMARY | |||
|
1YP2S94RVH
Created by
admin on Sat Dec 16 17:20:47 GMT 2023 , Edited by admin on Sat Dec 16 17:20:47 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
PLASMA
|
||
|
METABOLITE -> PARENT |
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||